Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

255 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-01

Study Completion Date

2006-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

NCT00308191

COPD

COMPLETED PHASE3

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02238119

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528

Chronic Obstructive Pulmonary Disease Bronchitis Emphysema

COMPLETED PHASE4

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00239421

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Study in Subjects Greater Than 40 Years of Age With COPD

NCT00507234

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

formoterol fumarate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have a clinical history of COPD.
* Subjects must be current cigarette smokers or ex-smokers who stopped smoking at least 3 months prior to screening visit (V1). Subjects must have a smoking history of at least 10 pack-years (20 cigarettes per pack). Pack-years are calculated by multiplying the average packs of cigarettes smoked per day times the number of years.
* Subjects on stable inhaled corticosteroids are allowed to be enrolled and to remain on the treatment throughout the study.
* Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules.
* Subjects must agree to inform their usual treating physician of their participation in this study.
* Female subjects of childbearing potential must have a negative urine pregnancy test prior to the randomization of the study
* Nonpregnant women of childbearing potential must be using a medically acceptable, adequate form of birth control.

Exclusion Criteria

* Subjects have a current or past history of clinically relevant asthma.
* Subjects quit smoking less than 3 months prior to the Screening visit (V1).
* Subjects have required ventilator support for respiratory failure within the last year.
* Subjects have clinically significant lung disease other than COPD, e.g., bronchiectasis, sarcoidosis, pulmonary fibrosis, tuberculosis, etc.
* Subjects have undergone lobectomy, pneumonectomy or lung volume reduction surgery.
* Subjects have had lung cancer diagnosed or treated within the last five years.
* Subjects require nasal continuous positive airway pressure (CPAP) or bi-level positive airway pressure (Bi-PAP).
* Subjects have initiated pulmonary rehabilitation within the past 3 months.
* Subjects use oxygen \>= 2 liters per minute for \> 2 hours per day.
* Subjects require chronic or prophylactic treatment with antibiotics.
* Subjects have significant renal, hepatic, cardiovascular (including cor pulmonale), metabolic, neurologic, hematologic, gastrointestinal, cerebrovascular or other significant medical illness or disorder which, in the judgment of the Investigator, may interfere with the study or require treatment which may affect the evaluation of efficacy and safety of the study drug.
* Subjects have clinically significant abnormalities on chest x-ray (other than evidence of COPD) at the Screening visit or within the previous year.
* Women are pregnant or breast-feeding.
* Subjects cannot adhere to the concomitant medications restrictions and prohibitions.
* Subjects have used any investigational product within 30 days, or 3 months for any biologic of unknown half-life, prior to the Baseline Visit (V3).
* Subjects are part of the staff or a family member of the staff personnel directly involved with this study.
* Subjects have chronic narrow-angle glaucoma.
* Subjects have symptomatic prostatic hyperplasia or bladder-neck obstruction.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No